Looking ahead at 2020, we anticipate a ballot crowded with initiatives, many of which could have a significant impact on California’s life sciences industry. The issues being covered range from consumer privacy, which we have previously discussed at length, to commercial property taxes and funding for California’s stem cell agency.
The enactment of the California Consumer Privacy Act of 2018 (AB 375) (CCPA) brought sweeping restrictions on the collection and use of consumer information. A clean-up bill that same year, SB 1121 (Dodd), added key exceptions to the CCPA to help protect clinical trials and other biomedical research from unintended consequences, including exceptions for, among other things, protected health information (PHI) under federal law and information collected as part of a clinical trial subject to various laws and guidelines.
While the 2018 legislative year marked arguably the most successful year ever for CLSA in Sacramento and provided a number of major policy issues on which to focus our energy, the 2019 legislative year was “death by a thousand cuts,” requiring CLSA to spread its attention broadly across a host of issues outside of our traditional areas of focus.
On Oct. 22, CLSA, in partnership with Allergan and Edwards Lifesciences, hosted facility tour and roundtable discussion with the nearly 40 personnel, including state legislators, legislative staff, the Orange County Medical Association, and other key stakeholders to educate policymakers and stakeholders on the value of life sciences innovation in Orange County.
Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
With the impending January 1, 2020 effective date of the California Consumer Privacy Act (CCPA), the Legislature considered multiple bills this year that sought to clarify the law’s requirements and facilitate businesses’ compliance.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Tom Umberg (D-Santa Ana). We look forward to working with Senator Umberg and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Lena Gonzalez (D-Long Beach). We look forward to working with Senator Gonzalez and her team to advance policies that improve patient health and bring positive change for California patients and their families.
While fewer bills directly targeting the biopharmaceutical industry were introduced this year, which was likely due in large part to Governor Newsom’s executive order on state prescription purchasing, CLSA strongly supported several bills that reached the Governor’s desk and helped prevent a number of bills of concern from reaching his desk.
“We all agree that drug prices are high, but a proposal before the Legislature would make that situation worse, even as it seeks to solve the problem.” Read more about AB 824 in CalMatters.